PHVS
Pharvaris N.V.
Healthcare · Biotechnology · NMS
$29.47
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$2.1B
Trailing P/E
Forward P/E
-10.69
Rev Growth
Profit Margin
0.0%
ROE
-73.0%
Analyst Target
$41.72
Recommendation
STRONG BUY
About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow0.0
Moat40.0
Balance Sheet95.1
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: WATCH · Score: 39.9 · Rank: #4260
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$1.7B
Price/Book
6.12
Beta
-2.335
Analysts
13
Total Debt
$738.9K
Rec. Mean
1.38
Short Ratio
1.60
Short % Float
0.0%
Employees
134

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 13 analysts at Strong Buy.
Price: $29.47 | Target: $46.59 (+58%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+58%
The Fundamentals
Profit Margin0.0%
ROE-73.0%
Forward P/E-10.7
Market Cap$2.1B
Position Sizing Scenarios
Stop: $25.05 (-15%) | Entry: $29.47
SharesCostProfit to TargetR:R
To Consensus ($46.59, 13 analysts)
10$294.70+$171.20 (58%)3.9R
50$1,473.50+$856.00 (58%)3.9R
100$2,947.00+$1,712.00 (58%)3.9R
Risk Factors
  • No elevated risk flags in current data
The Verdict
Pharvaris N.V. holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
59.3
Risk Grade
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-6.1%
worst expected daily loss, 19 in 20 days
CVaR 95%
-8.1%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
0.58
above 1.0 is good
Max Drawdown
-52.7%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
75
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
LOWER_HALF
Beta
Relative Volume
1.7x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
MPLT0.333
MGTX0.308
SYRE0.285
SNDX0.282
IDYA0.281
Inverse Correlated
TickerCorrelation
ALEC.AE-0.252
ALFIRDOUS.AE-0.172
ENGRO.KA-0.162
PRN.L-0.148
ITHMR.AE-0.125
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Wednesday
Worst Day
Thursday
Best Month
Apr
Worst Month
May
Fri-Mon Effect
0.30383097984325935
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+5.8%
3M Return
+6.6%
6M Return
+17.6%
12M Return
+88.5%
Momentum Rank
#1018
Momentum Signal
UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access